Incyte Corporation vs Western Digital Corp — how do they compare? Incyte Corporation trades at $113.06 (market cap $22.85B), while Western Digital Corp trades at $393.93 (market cap $147.23B). The key difference: Western Digital Corp is far larger — about 6.4× Incyte Corporation's market cap, and Western Digital Corp pays a 0.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Western Digital Corp for 37 Days on average.
| INCY | WDC | |
|---|---|---|
Market Cap | $22.85B | $147.23B |
Volume | 1,927,029 | 9,341,468 |
Sector | Health | Technology |
52-Week High | $129.93 | $746.23 |
52-Week Low | $83.80 | $113.13 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $18.35B | $146.70B |
Dividend Yield | — | 0.15% |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Western Digital (WDC) trades at $394.13, down 2.73% amid concerns about increased competition from Toshiba's planned HDD production expansion. The stock shows strong fundamentals with three consecutive earnings beats and robust profitability metrics including 71.97% net margin and 131.02% ROE. Technical indicators are bearish with the price testing key support at $387, while analyst consensus remains strongly bullish with a $647.58 price target representing 64% upside potential.
Despite near-term competitive pressures, WDC's dominant market position in AI storage and improving financial performance support long-term growth prospects. Key risks include pricing pressure from increased industry capacity and execution challenges in maintaining cost-per-terabyte reductions. The current valuation at 14.61 P/E appears attractive relative to growth expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →